Compare GPCR & MMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GPCR | MMS |
|---|---|---|
| Founded | 2016 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Business Services |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.2B |
| IPO Year | 2023 | 1997 |
| Metric | GPCR | MMS |
|---|---|---|
| Price | $49.09 | $58.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $103.17 | N/A |
| AVG Volume (30 Days) | 534.2K | ★ 625.5K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.02% |
| EPS Growth | N/A | ★ 10.42 |
| EPS | N/A | ★ 5.45 |
| Revenue | N/A | ★ $2,392,236,000.00 |
| Revenue This Year | N/A | $0.44 |
| Revenue Next Year | N/A | $5.15 |
| P/E Ratio | ★ N/A | $10.60 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.26 | $52.73 |
| 52 Week High | $94.90 | $100.00 |
| Indicator | GPCR | MMS |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 50.78 |
| Support Level | $43.76 | $56.97 |
| Resistance Level | $52.60 | $62.78 |
| Average True Range (ATR) | 2.52 | 2.07 |
| MACD | -0.29 | -0.02 |
| Stochastic Oscillator | 22.33 | 45.62 |
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.